Does early PTH treatment compromise bone strength? The balance between remodeling, porosity, bone mineral, and bone size (Q36203360)

12 August 2017

1 reference

title

Does early PTH treatment compromise bone strength? The balance between remodeling, porosity, bone mineral, and bone size (English)

1 reference

12 August 2017

David B Burr

1

1 reference

12 August 2017

1 March 2005

1 reference

Current osteoporosis reports

12 August 2017

1 reference

12 August 2017

3

1 reference

12 August 2017

1

1 reference

12 August 2017

19-24

1 reference

https://scigraph.springernature.com/pub.10.1007/s11914-005-0023-9

12 August 2017

0 references

cites work

Changes in geometry and cortical porosity in adult, ovary-intact rabbits after 5 months treatment with LY333334 (hPTH 1-34)

1 reference

12 December 2020

Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate

1 reference

12 December 2020

Comparison of early bone histomorphometric effects of parathormone and alendronate in osteoporotic women

1 reference

12 December 2020

Treatment with human parathyroid hormone (1-34) for 18 months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomolgus monkeys (Macaca fascicularis)

1 reference

12 December 2020

Teriparatide [PTH(1-34)] strengthens the proximal femur of ovariectomized nonhuman primates despite increasing porosity.

1 reference

12 December 2020

Treatment of osteoporosis with parathyroid peptide (hPTH 1–34) and oestrogen: increase in volumetric density of iliac cancellous bone may depend on reduced trabecular spacing as well as increased thickness of packets of newly formed bone

1 reference

12 December 2020

The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis

1 reference

12 December 2020

Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal

1 reference

12 December 2020

Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers.

1 reference

12 December 2020

Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis

1 reference

12 December 2020

Basic biomechanical measurements of bone: a tutorial

1 reference

12 December 2020

The effects of PTH (1-34) on bone structure and strength in ovariectomized monkeys

1 reference

12 December 2020

hPTH 1-34 treatment of osteoporosis with added hormone replacement therapy: biochemical, kinetic and histological responses

1 reference

12 December 2020

Geometric structure of the femoral neck measured using dual-energy x-ray absorptiometry

1 reference

12 December 2020

Anabolic effects of human biosynthetic parathyroid hormone fragment (1-34), LY333334, on remodeling and mechanical properties of cortical bone in rabbits

1 reference

12 December 2020

Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study

1 reference

12 December 2020

Restoration of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1-34) and 1,25-dihydroxyvitamin D

1 reference

12 December 2020

Intermittently administered human parathyroid hormone(1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys

1 reference

12 December 2020

Efficacy and Safety of Human Parathyroid Hormone-(1–84) in Increasing Bone Mineral Density in Postmenopausal Osteoporosis

1 reference

12 December 2020

Effects of human parathyroid hormone (1-34), LY333334, on bone mass, remodeling, and mechanical properties of cortical bone during the first remodeling cycle in rabbits

1 reference

12 December 2020

The Effects of Parathyroid Hormone, Alendronate, or Both in Men with Osteoporosis

1 reference

12 December 2020

Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis

1 reference

12 December 2020

Histomorphometric evidence for increased bone turnover without change in cortical thickness or porosity after 2 years of cyclical hPTH(1-34) therapy in women with severe osteoporosis

1 reference

12 December 2020

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

1 reference

12 December 2020

Bone densitometric and histomorphometric responses to sequential human parathyroid hormone (1-38) and salmon calcitonin in osteoporotic patients

1 reference

12 December 2020

Mid-femur geometry and biomechanical properties in 15- to 18-yr-old female athletes

1 reference

12 December 2020

The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis

1 reference

12 December 2020

Associations of hormone replacement therapy with bone structure and physical performance among postmenopausal women.

1 reference

12 December 2020

10.1007/S11914-005-0023-9

Identifiers

DOI

1 reference

12 August 2017

1 reference

PubMed ID

16036097